Phat Tung Ma

Dr. Phat Tung Ma

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Medicine
Verified
Journal Article
Open access
NTNam Quang Tran
Nam Quang Tran
STSteven D. Truong
Steven D. Truong
PMPhat Tung Ma
Phat Tung Ma
CHChi Khanh Hoang
Chi Khanh Hoang
BLBao Hoang Le
Bao Hoang Le
DDDuc-Minh Do
Duc-Minh Do
Type 2 diabetes mellitus (T2DM) is a genetically influenced disease, but few studies have been performed to investigate the genetic basis of T2DM in Vietnamese subjects. Thus, the potential associations of KCNJ11 and ABCC8 single nucleotide polymorphisms (SNPs) with T2DM were investigated in a Kinh Vietnamese population. A cross-sectional study consisting of 404 subjects including 202 T2DM cases and 202 non-T2DM controls was designed to examine the potential associations of 4 KCNJ11 and ABCC8 SNPs (rs5219, rs2285676, rs1799859, and rs757110) with T2DM. Genotypes were identified based on restriction fragment length polymorphism and tetra-primer amplification refractory mutation system polymerase chain reaction. After statistically adjusting for age, sex, and BMI, rs5219 was found to be associated with an increased risk of T2DM under 2 inheritance models: codominant (OR = 2.15, 95% confidence intervals [CI] = 1.09–4.22) and recessive (OR = 2.08, 95%CI = 1.09–3.94). On the other hand, rs2285676, rs1799859, and rs757110 were not associated with an increased risk of T2DM. Haplotype analysis elucidated a strong linkage disequilibrium between the 3 SNPs, rs5219, rs2285676, and rs757110. The haplotype rs5219(A)/rs2285676(T)/rs757110(G) was associated with an increased risk of T2DM (OR = 1.42, 95%CI = 1.01–1.99). The results show that rs5219 is a lead candidate SNP associated with an increased risk of developing T2DM in the Kinh Vietnamese population. Further functional characterization is needed to uncover the mechanism underlying the potential genotype-phenotype associations.

1 April 2023 in Endocrinology, Diabetes & Metabolism Case Reports
Verified
Journal Article
Open access
PDF file
NTNam Quang Tran
Nam Quang Tran
CPChien Cong Phan
Chien Cong Phan
TVTran Bao Vuong
Tran Bao Vuong
TTThang Viet Tran
Thang Viet Tran
PMPhat Tung Ma
Phat Tung Ma
Summary Mitochondrial diseases are a group of rare diseases presenting with heterogeneous clinical, biochemical, and genetic disorders caused by mutations in the mitochondrial or nuclear genome. Multiple organs can be affected, particularly those with high energy demand. Diabetes is a common endocrine manifestation of mitochondrial diseases. The onset of mitochondrial diabetes can be latent or acute, and the presenting phenotype can be type 1- or type 2-like. Studies show that diabetes ais associated with latent progression of cognitive decline in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. Herein, we report a case of rapid cognitive decline after the acute onset of diabetes in a patient with MELAS syndrome. The patient was a 36-year-old woman who was hospitalized due to hyperglycemic crisis and seizures. She was diagnosed with MELAS syndrome two years previously, and had gradually progressing dementia and hearing loss. However, following the acute onset of diabetes, she developed rapid cognitive decline and loss of ability to perform daily activities. In conclusion, the acute onset of diabetes could be an associated risk factor for rapid cognitive decline in patients with MELAS syndrome. Thus, these patients as well as healthy carriers with related genetic mutations should undergo diabetes education and screening tests. Moreover, clinicians should be aware of the possibility for acute onset of hyperglycemic crisis, particularly in the presence of triggering factors. Learning points Diabetes is a common endocrine manifestation of mitochondrial diseases, presenting with a type 1- or type 2-like phenotype depending on the level of insulinopenia. Metformin should be avoided in patients with mitochondrial diseases to prevent metformin-induced lactic acidosis. Mitochondrial diabetes can manifest before or after the onset of MELAS syndrome. In patients with MELAS syndrome, diabetes can initially manifest with a life-threatening severe hyperglycemic crisis and can cause rapid cognitive decline. Diabetes screening tests (e.g. hemoglobin A1c, oral glucose tolerance test, or random blood glucose level measurement) should be performed either systematically or in the presence of symptoms, particularly after triggering events. Genetic testing and counseling should be provided to patients and their families for the purpose of better understanding the inheritance, progression, and possible outcomes of the disease. Abstract Summary Mitochondrial diseases are a group of rare diseases presenting with heterogeneous clinical, biochemical, and genetic disorders caused by mutations in the mitochondrial or nuclear genome. Multiple organs can be affected, particularly those with high energy demand. Diabetes is a common endocrine manifestation of mitochondrial diseases. The onset of mitochondrial diabetes can be latent or acute, and the presenting phenotype can be type 1- or type 2-like. Studies show that diabetes ais associated with latent progression of cognitive decline in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome. Herein, we report a case of rapid cognitive decline after the acute onset of diabetes in a patient with MELAS syndrome. The patient was a 36-year-old woman who was hospitalized due to hyperglycemic crisis and seizures. She was diagnosed with MELAS syndrome two years previously, and had gradually progressing dementia and hearing loss. However, following the acute onset of diabetes, she developed rapid cognitive decline and loss of ability to perform daily activities. In conclusion, the acute onset of diabetes could be an associated risk factor for rapid cognitive decline in patients with MELAS syndrome. Thus, these patients as well as healthy carriers with related genetic mutations should undergo diabetes education and screening tests. Moreover, clinicians should be aware of the possibility for acute onset of hyperglycemic crisis, particularly in the presence of triggering factors. Learning points Diabetes is a common endocrine manifestation of mitochondrial diseases, presenting with a type 1- or type 2-like phenotype depending on the level of insulinopenia. Metformin should be avoided in patients with mitochondrial diseases to prevent metformin-induced lactic acidosis. Mitochondrial diabetes can manifest before or after the onset of MELAS syndrome. In patients with MELAS syndrome, diabetes can initially manifest with a life-threatening severe hyperglycemic crisis and can cause rapid cognitive decline. Diabetes screening tests (e.g. hemoglobin A1c, oral glucose tolerance test, or random blood glucose level measurement) should be performed either systematically or in the presence of symptoms, particularly after triggering events. Genetic testing and counseling should be provided to patients and their families for the purpose of better understanding the inheritance, progression, and possible outcomes of the disease.

5 June 2025
Verified
Book Chapter
Closed access
PDF file
PMPhat Tung Ma
Phat Tung Ma
NTNam Quang Tran
Nam Quang Tran
LLLinh Hoang Gia Le
Linh Hoang Gia Le
NLNien Vinh Lam
Nien Vinh Lam

Verified
Journal Article
Open access
PDF file
PMPhat Tung Ma
Phat Tung Ma
NTNam Quang Tran
Nam Quang Tran
MHMinh Vu Phuc Ha
Minh Vu Phuc Ha
GLGia-Hoang Linh Le
Gia-Hoang Linh Le
NLNien Vinh Lam
Nien Vinh Lam
Metabolic syndrome (MtS) is a growing global health concern, with genetic factors playing a significant role in its development. This study aimed to examine the association between ADIPOQ polymorphisms and MtS, as well as their relationships with adiponectin levels in the Vietnamese population. Metabolic parameters and genotyping data were collected from 160 individuals diagnosed with MtS according to the 2005 International Diabetes Federation criteria, and 160 control subjects. The results reveal a significant association between rs266729 and MtS, with a log-additive OR = 1.46 (95% CI: 1.02–2.09, p = 0.038). Carriers of the G allele also exhibit lower median adiponectin levels: 6.69 (3.84–10.52) µg/mL for C/C, 6.55 (3.32–9.52) µg/mL for G/C, and 4.28 (3.14–6.38) µg/mL for G/G, p for trend = 0.036. In contrast, the associations of rs2241766 and rs1501299 with MtS did not reach statistical significance in this cohort. However, adiponectin levels also show a trend of progressively decreasing with increasing numbers of minor alleles in the genotypes, particularly in the control group, p for trend = 0.02 and 0.044, respectively. These findings underscore the importance of genetic variations in regulating adiponectin, especially during the early stages of metabolic disturbances, and call for further research to assess their clinical significance.

9 January 2026 in JMIR Formative Research
Verified
Journal Article
Open access
Sze May NgSze May Ng
Sze May Ng
SNSoe Nyi Nyi
Soe Nyi Nyi
Muhammad Yazid JalaludinMuhammad Yazid Jalaludin
Muhammad Yazid Jalaludin
AZAzriyanti Anuar Zaini
Azriyanti Anuar Zaini
PMPhat Tung Ma
Phat Tung Ma
AFAnne-Charlotte Ficheroulle
Anne-Charlotte Ficheroulle
Background: Type 1 diabetes remains an underrecognized and challenging condition across Southeast Asia, where many countries face limited health care infrastructure, shortages of trained health care professionals, inconsistent access to diabetes education, and a lack of culturally appropriate resources in local languages. These barriers contribute to delayed diagnosis, suboptimal self-management, high rates of diabetic ketoacidosis, and inequities in care. During the COVID-19 pandemic, Action4Diabetes, a nonprofit organization working with local health care professionals and diabetes associations across Southeast Asia, developed HelloType1, a multilingual digital educational platform designed to improve awareness, education, and access to credible type 1 diabetes information. The platform was launched sequentially in Cambodia in 2021, Vietnam and Thailand in 2022, and Malaysia in 2023 through formal memorandums of understanding with local partners. Objective: This study aimed to evaluate the reach, platform usage, and online engagement of the HelloType1 digital educational platform across Southeast Asia between 2021 and 2024. Methods: Website analytics from Google Analytics 4 and Meta Business Suite metrics were descriptively analyzed to assess digital reach and engagement across countries. Metrics were compared over time and by country to examine patterns of platform uptake and user engagement. Results: HelloType1 demonstrated substantial growth between 2021 and 2024. Total unique website users increased from 1178 in 2021 to 40,361 in 2024, representing a marked expansion in regional reach. Pageviews rose from 4644 in 2021 to 83,689 in 2024, suggesting increasing content use and user platform engagement. By 2024, most website visits originated from organic search engines. Platform use was predominantly mobile-based, particularly in Vietnam, Thailand, and Malaysia, with the strongest engagement among adults aged 25 to 54 years. Facebook followers increased from 940 to 4553, and average engagement rates rose between 2022 and 2024. Cambodia achieved the highest number of Facebook interactions, whereas Thailand demonstrated the highest engagement rate. Content-level analysis showed that practical self-management topics, including blood glucose monitoring, insulin treatment, nutrition and exercise, complications, and emotional support, generated high levels of reach and interaction. Conclusions: HelloType1 demonstrates strong growth, mobile-first use, search-driven visibility, and engagement with practical self-management content. These findings support the feasibility and potential utility of a low-cost, multilingual digital education model, while future studies should evaluate its effects on knowledge, behavior, and clinical outcomes.

16 September 2025 in Tạp chí Y học Việt Nam
Verified
Journal Article
Open access
PDF file
PMPhat Tung Ma
Phat Tung Ma
NQNam Trần Quang
Nam Trần Quang
MPMinh Hà Vũ Phúc
Minh Hà Vũ Phúc
NVNiên Lâm Vĩnh
Niên Lâm Vĩnh
Đặt vấn đề: Gan nhiễm mỡ liên quan đến rối loạn chuyển hóa (MASLD) có tỉ lệ cao ở bệnh nhân có yếu tố nguy cơ tim mạch chuyển hóa. Nghiên cứu được thực hiện nhằm xác định tỉ lệ MASLD ở bệnh nhân có hội chứng chuyển hóa (HCCH). Đối tượng và phương pháp nghiên cứu: Đây là một nghiên cứu hồi cứu được thực hiện trên 90 bệnh nhân HCCH tại Bệnh viện Đại học Y Dược Thành phố Hồ Chi Minh trong khoảng thời gian từ tháng 9/2023 đến tháng 4/2024. MASLD được chẩn đoán theo tiêu chí của đồng thuận Delphi năm 2023 và HCCH được chẩn đoán theo tiêu chí của Liên đoàn đái tháo đường thế giới (IDF) 2006. Kết quả: Dân số nghiên cứu có tuổi trung bình là 49,35 ± 8,39 với 67,78% tỉ lệ nữ, Chỉ số khối cơ thể (BMI) trung bình là 26,23 ± 2,79 kg/m2. Có 68 bệnh nhân HCCH thỏa tiêu chí MASLD, chiếm tỉ lệ 68,9%, Nhóm bệnh nhân HCCH có MASLD có BMI cao hơn có ý nghĩa so với nhóm không có MASLD (p < 0,05). Kết luận: Nghiên cứu cho thấy tính phổ biến của MASLD ở bệnh nhân HCCH, đặc biệt ở người béo phì. Do đó, cần thiết có sàng lọc và can thiệp sớm MASLD nhằm hạn chế nguy cơ tiến triển các bệnh gan mạn tính.